| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 30 | -2,070 | 30 | 1,240 | 1,110 |
| Sales Growth | +101.45% | -7,000.00% | -97.58% | +11.71% | -38.67% |
| Net Income | -960 | -670 | -8,430 | -2,630 | 1,470 |
| Net Income Growth | -43.28% | +92.05% | -220.53% | -278.91% | +183.52% |
Vyome Holdings Inc (HIND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31